|
|
 Previous Article | Table of Contents | Next Article 
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA)
EH Estey, R Kurzrock, HM Kantarjian, SM O'Brien, KB McCredie, M Beran, C Koller, MJ Keating, C Hirsch-Ginsberg and YO Huh
Department of Hematology, University of Texas M.D. Anderson Cancer Center,
Houston 77030.
We administered one course of 2-chlorodeoxyadenosine (2CdA) at 4 mg/m2
daily for 7 days by continuous intravenous infusion to 46 patients with
hairy cell leukemia. Complete remissions occurred in 36 patients (78%; 95%
confidence limits, 63% to 89%), partial remissions in five (11%), and a
minor response in one. One patient died of candida sepsis 3 weeks after
beginning treatment and three patients were clearly resistant to therapy.
These three either had morphologically atypical hairy cells, less than 20%
of which expressed Ig light chain on the cell surface, or had failed prior
treatment with deoxycoformycin and interferon-alpha. At a median of 37
weeks since discontinuation of therapy, recurrent thrombocytopenia has
developed in one patient, whose marrow remains normal, while a bone marrow
relapse has occurred in another patient, whose blood counts remain normal.
Treatment produced a greater than 50% decrease in neutrophil count in 26
patients, which lasted 3 to 4 weeks and was associated with an increased
incidence of febrile episodes. These episodes occurred in 21 patients but
were associated with documented infection in only four patients. Decreases
in the number of CD4+ lymphocytes appeared to occur regularly after
treatment and have persisted for a median of 18 weeks without obvious
clinical significance. Although years of follow-up will be needed, our
results confirm Piro et al's observation (N Engl J Med 322: 1117, 1990)
that 2CdA appears to be highly effective in the treatment of hairy cell
leukemia.
Volume 79,
Issue 4,
pp. 882-887,
02/15/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Braiteh and R. Kurzrock
Uncommon tumors and exceptional therapies: paradox or paradigm?
Mol. Cancer Ther.,
April 1, 2007;
6(4):
1175 - 1179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O. Wanko and C. de Castro
Hairy Cell Leukemia: An Elusive but Treatable Disease
Oncologist,
July 1, 2006;
11(7):
780 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi, J. L. Jorgensen, S. M. O'Brien, S. Verstovsek, C. A. Koller, S. Faderl, F. J. Giles, A. Ferrajoli, W. G. Wierda, S. Odinga, et al.
Eradication of minimal residual disease in hairy cell leukemia
Blood,
June 15, 2006;
107(12):
4658 - 4662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Ravandi and S. O'Brien
Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1660 - 1674.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Chadha, A. W. Rademaker, P. Mendiratta, B. Kim, D. M. Evanchuk, D. Hakimian, L. C. Peterson, and M. S. Tallman
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience
Blood,
July 1, 2005;
106(1):
241 - 246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Thomas, S. O'Brien, C. Bueso-Ramos, S. Faderl, M. J. Keating, F. J. Giles, J. Cortes, and H. M. Kantarjian
Rituximab in relapsed or refractory hairy cell leukemia
Blood,
December 1, 2003;
102(12):
3906 - 3911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. von Rohr, S.-F. H. Schmitz, A. Tichelli, U. Hess, D. Piguet, M. Wernli, N. Frickhofen, G. Konwalinka, G. Zulian, M. Ghielmini, et al.
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
Ann. Onc.,
October 1, 2002;
13(10):
1641 - 1649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Federico, P. L. Zinzani, A. Frassoldati, M. Vinceti, A. Mode, L. Annino, T. Chisesi, G. Pagnucco, R. Invernizzi, M. Spriano, et al.
Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up
J. Clin. Oncol.,
February 1, 2002;
20(3):
638 - 646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, D. Hakimian, K. J. Kopecky, S. Wheaton, E. Wollins, K. Foucar, P. A. Cassileth, T. Habermann, M. Grever, J. M. Rowe, et al.
Minimal Residual Disease in Patients with Hairy Cell Leukemia in Complete Remission Treated with 2-Chlorodeoxyadenosine or 2'-Deoxycoformycin and Prediction of Early Relapse
Clin. Cancer Res.,
July 1, 1999;
5(7):
1665 - 1670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saven, C. Burian, J. Adusumalli, and J. A. Koziol
Filgrastim for Cladribine-Induced Neutropenic Fever in Patients With Hairy Cell Leukemia
Blood,
April 15, 1999;
93(8):
2471 - 2477.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saven, C. Burian, J. A. Koziol, and L. D. Piro
Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment
Blood,
September 15, 1998;
92(6):
1918 - 1926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. C. Kluin-Nelemans, M. G.D. Kester, L. van deCorput, P. P.C. Boor, J. E. Landegent, J. J.M. van Dongen, R. Willemze, and J.H. F. Falkenburg
Correction of Abnormal T-Cell Receptor Repertoire During Interferon-alpha Therapy in Patients With Hairy Cell Leukemia
Blood,
June 1, 1998;
91(11):
4224 - 4231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K Morris, J. M Kolesar, and J. G Kuhn
Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine
Journal of Oncology Pharmacy Practice,
June 1, 1997;
3(2):
94 - 109.
[PDF]
|
|
|
|
|
|
|
P. Hentosh and M. Tibudan
2-Chloro-2'-deoxyadenosine, an Antileukemic Drug, Has an Early Effect on Cellular Mitochondrial Function
Mol. Pharmacol.,
April 1, 1997;
51(4):
613 - 619.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Lauria, M. Bocchia, G. Marotta, D. Raspadori, P. Zinzani, and D. Rondelli
Weekly Administration of 2-Chlorodeoxyadenosine in Patients With Hairy-Cell Leukemia: A New Treatment Schedule Effective and Safer in Preventing Infectious Complications
Blood,
March 1, 1997;
89(5):
1838 - 1839.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fidias, B. A. Chabner, and M. L. Grossbard
Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders
Oncologist,
June 1, 1996;
1(3):
125 - 139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Gruber, F Geisen, R Sgonc, A Egle, A Villunger, G Boeck, G Konwalinka, and R Greil
2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA)
Stem Cells,
May 1, 1996;
14(3):
351 - 362.
[Abstract]
|
|
|
|
|
|
|
J. M. Kolesar, A. K. Morris, and J. G. Kuhn
Review : Purine nucleoside analogues: Fludarabine, pentostatin, and cladribine: Part 1: Fludarabine
Journal of Oncology Pharmacy Practice,
January 1, 1996;
2(3):
160 - 181.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Saven and L. Piro
Newer Purine Analogues for the Treatment of Hairy-Cell Leukemia
N. Engl. J. Med.,
March 10, 1994;
330(10):
691 - 697.
[Full Text]
|
|
|
|
|
|
|
S. O'Brien, H. Kantarjian, E. Estey, C. Koller, B. Robertson, M. Beran, M. Andreeff, S. Pierce, and M. Keating
Lack of Effect of 2-Chlorodeoxyadenosine Therapy in Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine Therapy
N. Engl. J. Med.,
February 3, 1994;
330(5):
319 - 322.
[Abstract]
[Full Text]
|
|
|
|
|
